Neoplasms

Digestive System Diseases

All Conditions

Symptoms and General Pathology

Rare Diseases

Stomach Neoplasms

Disease Progression

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Stomach Cancer

Paraffin tissue microarray slides prepared from normal tissue adjacent to tumor tissue removed during gastrectomy were retrieved from the biological sample library of the Northern Jiangsu People's Hospital.

Paraffin tissue microarray slides prepared from tumor tissue removed during gastrectomy were retrieved from the biological sample library of the Northern Jiangsu People's Hospital.

Collection of tumor tissue specimens during surgery

Collection of tumor tissue specimens

Daorong Wang, M.D., Professor

Background：Gastric cancer is a globally important disease and the fifth most diagnosed malignant cancer in the world. Because it is usually diagnosed at an advanced stage, gastric cancer has a high mortality rate, making it the third most common cause of cancer-related death. Hot spots of gastric cancer incidence and mortality exist in East Asia, Eastern Europe and South America. It is still an urgent problem to find new diagnostic and prognostic markers and better understand the molecular mechanism of gastric cancer. Although radical resection and systemic chemotherapy have shown great improvement, the prognosis of gastric cancer (GC) patients is still depressing due to malignant proliferation and metastasis. Therefore, it is urgent to clarify the potential molecular mechanism of gastric cancer progression, which will contribute to the development of targeted therapy. Effective induction of tumor cell apoptosis is the most important feature of a new chemical agent for cancer treatment. There is increasing evidence that the cell cycle can act in concert with apoptosis to cause cell death under certain cellular stress conditions. A comprehensive understanding of the relationship between apoptosis and cell cycle is essential for developing effective cancer therapies.

PWP1 is also known as endonuclein, which contains five WD40 repeated domains and belongs to the WD40-repeated superfamily. It is highly expressed in human pancreatic adenocarcinoma, where it functions as a cell-cycle regulator. However, the normal function of Pwp1 is largely unknown. Previous research data show that PWP1 plays a key role in regulating biological functions such as RNA processing, signal transduction, gene expression, vesicle transport, cytoskeleton assembly and cell cycle progression. Whether the high expression of PWP1 is ubiquitous in tumors, the relationship between the high expression and clinicopathological factors of tumors, and the mechanism of PWP1 in tumors are still unclear. Further exploration of the molecular mechanism of PWP1 in GC may provide new ideas and therapeutic targets for GC treatment in the future, and benefit clinical patients.

Apply to the biological sample library for samples of tumor tissue and adjacent tissues preserved during surgery in gastric cancer patients. Subsequently, prepare tissue slices for immunohistochemical staining and compare the expression profiles between the two sample groups.

PWP1's Expression in Gastric Cancer.

PWP1 Affects Gastric Cancer Progression by Regulating p53 and JAK1 and Its Expression in Gastric Cancer.

Contains a large amount of personal information about patients and needs to be treated with caution.

Test the expression of PWP1 in adjacent tissues and tumor tissues of patients with gastrectomy for gastric cancer through the immunohistochemical.

Northern Jiangsu People's Hospital

Professor, M.D.

Skin and Connective Tissue Diseases

Breast Neoplasms

Breast Diseases

Skin Diseases

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Tubulin Modulators

Antimitotic Agents

Taxotere

Mothaffar Rimawi, MD

We, the investigators at Baylor Breast Care Cancer, are doing this study to learn how well Taxotere makes tumors become smaller. We are also doing this study to find out how well Taxotere treats the type of breast cancer that some patients have. We are asking patients to take part in this study because they have locally advanced breast cancer. Women with this breast cancer will usually receive chemotherapy medicines to reduce or shrink the cancer before surgery to take out the cancer. If patients choose to take part in this study, they will receive Taxotere and the combination of cyclophosphamide and doxorubicin. These medicines are part of the standard good medical care for this type of breast cancer. They are approved for the treatment of this problem. To help us learn how the patients' cancer responds to these medicines, we will take a small tissue sample (biopsy) of the patients' breast cancer before beginning treatment, one day after the first dose of treatment, once each week for the first three weeks of treatment, and when surgery is done as part of treatment for their cancer. These samples will be collected also to look at the biology of the patients' cancer. We will also use a new method called cDNA array technology, which lets us look at thousands of genes (coding information inside the cancer cell) at once. By looking at different genes in the breast cancer, we may learn important information about which cancers will respond to a chemotherapy medicine. We hope to learn if there are different gene patterns in patients whose tumors shrink or do not shrink with this chemotherapy medicine. This information may help us, in the future, to choose the right medicines for women with breast cancer so that they have the highest chance of their cancer shrinking with chemotherapy medicine. We cannot and do not know if patients will benefit if they take part in this study.

New treatment strategies are needed to improve the clinical outcome in breast cancer patients at high risk of tumor recurrence. Even with the best present combination chemotherapy, radiotherapy and surgery, the five-year rate of disease recurrence and death is at least 60% in patients with locally advanced breast cancer. Recent advances that may improve clinical outcome include the use of taxanes (paclitaxel and docetaxel), a new class of cytotoxic agents, with reported higher response rates than standard anthracycline-based chemotherapy. Understanding the in vivo mechanism of action of chemotherapeutic agents would also allow for rational combination of agents. For example, if apoptosis is the main mechanism of therapeutic action, then future developments in restoring function of p53 by gene therapy or treatment with apoptosis regulating molecules may prove to be important future advances in the treatment of cancer. If specific therapeutic targets and pathways are identified, new molecules with selective action against these targets may be developed, which may have potential for decreased toxicity with increased efficacy.

To this end, we undertook a Phase II clinical trial of neoadjuvant docetaxel (Taxotere) in patients with locally advanced breast cancer (H-8448), with the primary goal of defining the clinical efficacy and the biologic effects of docetaxel. The secondary aim of the study was to identify distinctive gene expression patterns predictive of response to docetaxel chemotherapy. For this, we proposed to use microarray expression technology (Affymetrix U95A) and allied validation technologies (e.g., IHC, western blot, quantitative RT-PCR) to identify and validate patterns of gene expression associated with chemotherapy sensitivity or resistance.

The purpose of this Phase II extension study is to determine the biologic effects of docetaxel (Taxotere), to identify gene expression profiles predictive of response, and to further describe the efficacy of Taxotere in women with locally advanced breast cancer. In addition to surgical operability and clinical response, the endpoints will include the comparison of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Taxotere. Expression arrays will be used to identify and validate patterns of gene expression associated with Taxotere sensitivity or resistance.

Clinical study: A diagnostic core biopsy will be performed prestudy, and tissue obtained from this will be available for analysis. Other required baseline investigations, including CBC, kidney function tests, liver function tests, EKG, and pregnancy tests, are part of the standard of care. Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.

Core biopsies: Core biopsies for biologic marker evaluation will be performed prestudy (excess from diagnostic biopsy), and on days 2, 8, 15, and 22 following entry into study. Tissue for analysis will also be obtained at surgery. Prestudy biopsy and specimen at surgery will be part of standard of care, while four additional biopsies will be performed solely for research purposes only. Thus, a total of six biopsies will be obtained: prestudy, day 2, day 8, day 15, day 22, and at surgery.

Biologic markers to be assessed: Docetaxel (Taxotere) may produce a therapeutic response by induction of programmed cell death or by inhibition of cell division. Hence, apoptosis by TUNEL assay and other regulatory molecules (p53, bcl-2 and bax) will be measured. Proliferation will be assessed by measuring Ki67. From animal models, antiangiogenic effects with docetaxel (Taxotere) have been described, and this would be assessed in these clinical samples by measuring VEGF and microvessel counting (CD31). Remaining frozen tissue will be snap frozen and stored temporarily in liquid nitrogen for microarray analysis.

Side effects with chemotherapy are part of standard of care. The chemotherapy treatments used in this protocol have all been widely used in breast cancer patients and represent some of the most effective treatments for this condition. Some known effects for all chemotherapy include neutropenia, infections, anemia, cardiotoxicity, congestive heart failure, alopecia, nail discoloration, nausea, vomiting, fatigue, and loss of appetite.

Side effects from core biopsies: Risks associated with breast biopsy include bleeding, bruising, mild discomfort, and infection. Discomfort and minor complications from the four additional biopsy procedures will be minimized by use of experienced personnel.

Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer

An Extension Phase II Study of the Clinical and Biologic Effects of Docetaxel (Taxotere) in Patients With Locally Advanced Breast Cancer

United States Department of Defense

Baylor Breast Care Center

Gland and Hormone Related Diseases

Thyroid Neoplasms

Thyroid Diseases

Adenoma

Endocrine System Diseases

Endocrine Gland Neoplasms

Head and Neck Neoplasms

Micronutrients

Anti-Infective Agents

Iodine

Cadexomer iodine

Ana K Sodré

Rosalinda Y Camargo

The uptake of iodide by thyroid cells requires the expression of sodium iodide symporter (NIS). Thyroid benign and malignant tumors have low iodide uptake activity. Previous studies of NIS expression with RT-PCR and immunohistochemistry showed divergent data. NIS protein was overexpressed in thyroid cancer. The aim of this study was to investigate the NIS transcript levels and its presence and localization in 30 samples of thyroid tumors (14 benign and 16 malignant) and in their surrounding non-tumoral tissues (NT), by real time RT-PCR and immunohistochemistry, respectively. Our results revealed lower gene expression in 78.6% of the benign tumors and 100% of the carcinomas when compared with the NT samples, using GHPDH as a housekeeping gene. Immunohistochemical staining revealed presence of NIS protein in 100% of the non-tumoral samples, 100% of the benign tumors and 93.75% of the malignant tumors. NIS protein was identified at basolateral membrane in 23.3% of non-tumoral samples, 14.3% of benign and 12.5% of malignant tumors. Stronger cytoplasmatic immunostaining of NIS protein was detected in 64.3% of benign tumors and in 87.5% of malignant tumors when compared to NT. Association between low gene expression and strong cytoplasmatic immunostaining was found in 50% of benign tumors and 87.5% of malignant tumors. We concluded that the reduced NIS gene expression in thyroid tumors associated with strong intracytoplasmatic staining may be due to its incapacity to migrate to cellular membrane.

The aim of this study was to quantify NIS transcript levels by real time PCR and to determine the presence and cellular localization of NIS protein by immunohistochemistry, in benign and malignant thyroid tumor cells and to compare with their paired surrounding non-tumoral cell. NIS expression was also compared to that of the TSHR

Expression of NIS Protein and mRNA in Thyroid Tumors

Significant Intracellular NIS Protein Associated With Low Levels of NIS Messenger RNA in Malignant Thyroid Tumors

Fundação de Amparo à Pesquisa do Estado de São Paulo

University of Sao Paulo

Pancreatic Neoplasms

Pancreatic Diseases

Pancreatic Cancer

pathologically confirmed pancreatic cancer patients

people without no neoplastic lesions and other organic diseases

The pancreatic cancer cohort and the healthy cancer-free patient cohort were divided according to pathology reports

Pathological

Lu Y Yuhua, phd

Chen Q QiYang, master

Lu Yuhua, phd

Chen Qiyang, master

Chen Q Qiyang, master

Background ： Pancreatic cancer is the most malignant tumor in the digestive system, with low level of early diagnosis and poor prognosis. There is a lack of high sensitive and specific molecular markers in the diagnosis, treatment and prognosis of pancreatic cancer.

Objective： To explore the expression of IGHD in pancreatic cancer and its correlation with clinical parameters, and to explore its prognostic value in patients with pancreatic cancer.

Methods： In this study, qRT-PCR was used to detect IGHD expression in peripheral blood. The expression of IGHD in pancreatic cancer and healthy individuals was compared. The PCR results were combined with clinical data of patients. To compare the expression of IGHD in different pancreatic cancer stages and evaluate whether IGHD expression in peripheral blood can be a potential biomarker for the diagnosis of pancreatic cancer, chi-square test was used to analyze the factors influencing the expression level of IGHD. Kaplan-Meier was used to analyze patient prognosis, and further Cox regression analysis was used to analyze the factors influencing patient prognosis and independent risk factors.

Methods：The expressions of IGHD in peripheral blood of about 30 patients with pancreatic cancer and more than 30 healthy controls were detected by qRT-PCR, and the differences of IGHD were analyzed.The expression of IGHD in pancreatic cancer and healthy individuals was compared. The PCR results were combined with clinical data of patients. To compare the expression of IGHD in different pancreatic cancer stages and evaluate whether IGHD expression in peripheral blood can be a potential biomarker for the diagnosis of pancreatic cancer, chi-square test was used to analyze the factors influencing the expression level of IGHD. Kaplan-Meier was used to analyze patient prognosis, and further Cox regression analysis was used to analyze the factors influencing patient prognosis and independent risk factors.

Pancreatic cancer is a disease of digestive system with a high degree of malignancy. The level of early diagnosis and therapeutic effect are limited by the research status of pancreatic adenocarcinoma. Conventional CT, MRI and other methods have a limited level of early diagnosis of pancreatic cancer, and EUS and endoscope-guided needle biopsy are in the stage of clinical trials. Studies on novel markers involve protein, miRNA, exosome, methylation, protein and genomics, but there is no mature and practical diagnostic method. Based on the current diagnosis, treatment and prognosis level of pancreatic cancer, I made a bold attempt to study the expression of IGHD in pancreatic cancer and their relationship with clinical parameters and prognosis level, so as to screen molecular markers conducive to diagnosis, treatment and prognosis of pancreatic cancer and provide data support for improving the diagnosis and treatment level of pancreatic cancer.

Peripheral blood from pancreatic cancer patients and healthy cancer-free patients

Expression and Clinical Significance of IGHD in Pancreatic Cancer

IGHD was highly expressed in pancreatic cancer patients , but low in the healthy cancer-free patients.

Patients with high expression of IGHD had lower prognosis. High expression of IGHD, T stage (T3T4), lymphatic metastasis and distant metastasis are independent risk factors for poor prognosis in patients with pancreatic cancer.

Expression level of IGHD in peripheral blood cells is a potential biomarker for the diagnosis of pancreatic cancer

Affiliated Hospital of Nantong University

Melanoma

Colorectal Neoplasms

Intestinal Neoplasms

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms by Histologic Type

Neoplasms, Nerve Tissue

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Neuroendocrine Tumor

Neuroepithelioma

Lillian Siu, MD

Bedard Philippe, MD

This is a feasibility study to look for genetic alterations in tissue and blood samples that may be useful in determining what treatments may be useful in the patient's cancer care.

As part of the study, patients will have archival tumor tissue collected, and have tumor biopsies and blood samples taken. The samples will be tested for genetic alterations, and the results will be discussed with the patient including potential treatments. If patients agree, after they have received treatment for their cancer and their disease progresses, a second biopsy procedure will be done.

Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples

A Feasibility Study of Genomic Profiling Methods and Timing of Sample Collection to Evaluate Clonal Evolution and Tumor Heterogeneity

Sequenom or MiSeq/TSCAP analysis from fresh core needle biopsy samples less than 4 weeks; sequenom or MiSeq/TSCAP analysis from fresh fine needle biopsy samples less than 8 weeks; MiSeq/NGS analysis from fresh core needle biopsy samples less than 8 weeks; MiSeq/NGS analysis from fresh fine needle biopsy samples less than 8 weeks

Ontario Institute for Cancer Research

Princess Margaret Hospital, Canada

University Health Network, Toronto

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
PWP1's Expression in Gastric Cancer.	NCT06392750	Diagnosis Gastric Cancer	Collection of t...	18 Years - 75 Years	Northern Jiangsu People's Hospital
Extension Neoadjuvant Taxotere: Study of the Effects of Taxotere in Patients With Breast Cancer	NCT00206453	Breast Cancer	Taxotere	18 Years -	Baylor Breast Care Center
Expression of NIS Protein and mRNA in Thyroid Tumors	NCT00459498	Tumors		18 Years - 80 Years	University of Sao Paulo
Expression and Clinical Significance of IGHD in Pancreatic Cancer	NCT05327400	Gene Expression	Pathological	18 Years - 80 Years	Affiliated Hospital of Nantong University
PWP1's Expression in Gastric Cancer.	NCT06392750	Diagnosis Gastric Cancer	Collection of t...	18 Years - 75 Years	Northern Jiangsu People's Hospital
Feasibility Study of Genomic Profiling Methods and Timing in Tumor Samples	NCT01703585	Colorectal Canc... Breast Cancer Gynecological C... Metastatic Eligible for Ph... Melanoma Cancer		18 Years -	University Health Network, Toronto

Spots Global Cancer Trial Database for expression

Every month we try and update this database with for expression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for expression

Every month we try and update this database with for expression cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for expression cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.